Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers

Experimental and Therapeutic Medicine

Volumn 11, Issue 1, 2016, Pages 164-170

  Sergides, Christakis ^a   Chirilă, Marinela ^b   Silvestro, Luigi ^c   Pitta, Daphne ^a   Pittas, Andreas ^a  

^a Medochemie Ltd   (Cyprus)

^b Medical Team Department   (Romania)

^c 3S Pharmacological Consultation and Research GmbH   (Germany)

Author keywords

Absorption; Bioavailability; Metabolism; Resveratrol; Safety; Supplements

Indexed keywords

RESVERATROL;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; ELECTROCARDIOGRAPHY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MIDDLE AGED; NORMAL HUMAN; OPEN STUDY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; YOUNG ADULT;

EID: 84949477526     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2895     Document Type: Article

References (34)

1. Arichi H, Kimura Y, Okuda H, Baba K, Kozawa M and Arichi S: Effects of stilbene components of the roots of Polygonum cuspidatum Sieb. et Zucc. on lipid metabolism. Chem Pharm Bull (Tokyo) 30: 1766-1770, 1982.
2. Baur JA and Sinclair DA: Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 5: 493-506, 2006.
3. Gambini J, López-Grueso R, Olaso-González G, Inglés M, Abdelazid K, El Alam IM, Bonet-Costa V, Borrás C and Viña J: Resveratrol: Distribution, properties and perspectives. Rev Esp Geriatr Gerontol 48: 79-88, 2013 (In Spanish).
4. Bertell AA and Das DK: Grapes, wines, resveratrol, and heart health. J Cardiovasc Pharmacol 54: 468-476 2009.
5. Bishayee A, Darvesh AS, Politis T and McGory R: Resveratrol and liver disease: From bench to bedside and community. Liver Int 30: 1103-1114, 2010.
6. Aires V, Limagne E, Cotte AK, Latruffe N, Ghiringhelli F and Delmas D: Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death. Mol Nutr Food Res 57: 1170-1181, 2013.
7. Aziz MH, Kumar R and Ahmad N: Cancer chemoprevention by resveratrol: In vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol 23: 17-28, 2003.
8. Asensi M, Medina I, Ortega A, Carretero J, Baño MC, Obrador E and Estrela JM: Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 33: 387-398, 2002.
9. Frémont L: Biological effects of resveratrol. Life Sci 66: 663-673, 2000.
10. Hung LM, Chen JK, Huang SS, Lee RS and Su MJ: Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 47: 549-555, 2000.
11. Bhat KPL, Kosmeder JW II and Pezzuto JM: Biological effects of resveratrol. Antioxid Redox Signal 3: 1041-1064, 2001.
12. de la Lastra CA and Villegas I: Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications. Mol Nutr Food Res 49: 405-430, 2005.
13. Ulrich S, Wolter F and Stein JM: Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in carcinogenesis. Mol Nutr Food Res 49: 452-461, 2005.
14. Jan-Kan C and Li-man H: Therapeutic use of resveratrol for hyperglycemia. US patent 2006/0034763 A1. Filed August 11, 2004; issued February 16, 2006.
15. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, et al: Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16: 1246-1252, 2007.
16. Agarwal B, Campen MJ, Channell MM, Wherry SJ, Varamini B, Davis JG, Baur JA and Smoliga JM: Resveratrol for primary prevention of atherosclerosis: Clinical trial evidence for improved gene in vascular endothelium. Int J Cardiol 166: 246-248, 2013.
17. Gu X, Creasy L, Kester A and Zeece M: Capillary electrophoretic determination of resveratrol in wines. J Agric Food Chem 47: 3223-3227, 1999.
18. Almeida L, Vaz-da-Silva M, Falcão A, Soares E, Costa R, Loureiro AL, Fernandes-Lopes C, Rocha JF, Nunes T, Wright L and Soares-da-Silva P: Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 53 (Suppl 1): S7-S15, 2009.
19. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C and Beaudeux JL: Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 54: 7-16, 2010.
20. Kuhnle G, Spencer JP, Chowrimootoo G, Schroeter H, Debnam ES, Srai SK, Rice-Evans C and Hahn U: Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun 272: 212-217, 2000.
21. Rotches-Ribalta M, Andres-Lacueva C, Estruch R, Escribano E and Urpi-Sarda M: Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine and grape extract tablets. Pharmacol Res 66: 375-382, 2012.
22. Brown A, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, et al: Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: Safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70: 9003-9011, 2010.
23. Wang D, Hang T, Wu C and Liu W: Identification of the major metabolites of resveratrol in rat urine by HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 829: 97-106, 2005.
24. Walle T: Bioavailability of resveratrol. Ann N Y Acad Sci 1215: 9-15, 2011.
25. Lu DL, Ding DJ, Yan WJ, Li RR, Dai F, Wang Q, Yu SS, Li Y, Jin XL and Zhou B: Influence of glucuronidation and reduction modifications of resveratrol on its biological activities. Chembiochem 14: 1094-1104, 2013.
26. Sergides C and Pittas A: Resveratrol compositions for use as dietary supplements. Patent EP2403479 A1. Filed March 3, 2010; issued January 11, 2012.
27. Liu X, Teng Z, Zhang Y, Huan M and Zhou S: High performance liquid chromatography-tandem mass spectrometric determination of resveratrol and its metabolites in rat tissues. Anal Lett 43: 557-569, 2010.
28. Muzzio M, Huang Z, Hu SC, Johnson WD, McCormick DL and Kapetanovic IM: Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC-MS/MS and their pharmacokinetics in dogs. J Pharm Biomed Anal 59: 201-208, 2012.
29. Biasutto L, Marotta E, Garbisa S, Zoratti M and Paradisi C: Determination of quercetin and resveratrol in whole blood-implications for bioavailability studies. Molecules 15: 6570-6579, 2010.
30. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowel JA, et al: Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70: 7392-7399, 2010.
31. Tomé-Carneiro J, Larrosa M, González-Sarrías A, Tomás-Barberán FA, García-Conesa MT and Espín JC: Resveratrol and clinical trials: The crossroad from in vitro studies to human evidence. Curr Pharm Des 19: 6064-6093, 2013.
32. Brasnyó P, Molnár GA, Mohás M, Markó L, Laczy B, Cseh J, Mikolás E, Szijártó IA, Mérei A, Halmai R, et al: Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106: 383-389, 2011.
33. Bhatt JK, Thomas S and Nanjan MJ: Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 32: 537-541, 2012.
34. Witte AV, Kerti L, Margulies DS and Flöel A: Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci 34: 7862-7870, 2014.